Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.50 |
| ▸ | CA1 | P00915 | 10/20 | 0.50 |
| ▸ | CA9 | Q16790 | 8/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20542290 | 1.00 | CA2 (0.50) | CA2CA1CA9CA12CA7 | |
| SCHEMBL24665746 | 1.00 | CA2 (0.50) | CA2CA1CA9CA12CA7 | |
| SCHEMBL7109060 | 1.00 | CA2 (0.50) | CA2CA1CA9CA12CA7 | |
| Bromide SCHEMBL5769748 | 0.98 | CA2 (0.48) | CA2CA1CA9CA12CA7 | |
| SCHEMBL276173 | 0.96 | CA2 (0.47) | CA2CA1CA9CA12CA7 | |
| SCHEMBL28480577 | 0.93 | TP53 (0.47) | CA2CA1CA9CA12CA7 | |
| SCHEMBL28486619 | 0.91 | CA2 (0.47) | CA2CA1CA9CA12CA7 | |
| SCHEMBL19028602 | 0.91 | CA2 (0.47) | CA2CA1CA9CA12CA7 | |
| SCHEMBL1487360 | 0.91 | CA2 (0.47) | CA2CA1CA9CA12CA7 | |
| Hydrochloric Acid SCHEMBL28210759 | 0.89 | CA2 (0.46) | CA2CA1CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230036933-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| US-20180104198-A1 | Pharmaceutical Composition, Methods for Treating and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036933-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | ENPP1, ENPP3, ENPP2 | CA2 3260/4885CA1 4479/4885CA9 4398/4885 |
| US-20180104198-A1 | Pharmaceutical Composition, Methods for Treating and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | CA2 2829/4885CA1 4580/4885CA9 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.